Nanchang Kangjie Medical & Sanitary Appliance Co.,Ltd!

这是描述信息
imgboxbg
Check category
/
/
/
China's medical appliance GDP will reach 1 trillion yuan in 2020

China's medical appliance GDP will reach 1 trillion yuan in 2020

  • Categories:Notice
  • Author:
  • Origin:
  • Time of issue:2018-07-10 16:52
  • Views:1

(Summary description)“Allthepartsofthebiopharmaceuticalindustrychainhaveinvestmentvalue”,commenteddirectoroftheMedicalScienceandTechnologyAchievementsTransformationCenterofChina,Mr.RuiGuozhong.Accordingtohim,overthepastfi

China's medical appliance GDP will reach 1 trillion yuan in 2020

(Summary description)“Allthepartsofthebiopharmaceuticalindustrychainhaveinvestmentvalue”,commenteddirectoroftheMedicalScienceandTechnologyAchievementsTransformationCenterofChina,Mr.RuiGuozhong.Accordingtohim,overthepastfi

  • Categories:Notice
  • Author:
  • Origin:
  • Time of issue:2018-07-10 16:52
  • Views:1
Information
  “All the parts of the biopharmaceutical industry chain have investment value”, commented director of the Medical Science and Technology Achievements Transformation Center of China, Mr. Rui Guozhong. According to him, over the past five years, the biomedical industry of China increased by 2 times in scale, from 422.3 billion yuan in 2005 to 1.0382 trillion yuan in 2009, exceeding the 1 trillion yuan mark for the first time, and hitting a record high in the stocks of related companies, up 19.8% over the same period last year. Who will be surrounded and picked up by capitals in the numerous segments of the biopharmaceutical industry? Current data shows that the growths of medical equipment, vaccines and other market segments are significant, which have a vast room for imagination.
 
  Medical equipment heading towards the trillion target
At the China International Medical Equipment Fair recently held in Shenyang, director of China Biotechnology Development Center under the Ministry of Science and Technology Mr. Wang Hongguang proposed the “one goal, three-step strategy, five focuses and six measures”. He said that in 2020, the technology level of China's medical devices has accessed the advanced level in the world, and the total output has reached 1,000 billion yuan. He told reporters that in the future, China would focus on the development of five areas: preventive health care, diagnostic detection, treatment and surgery, rehabilitation, and medical information”.
 
  Medical device companies are firmly optimistic about the future market space Related personnel from Shenzhen Mindray told reporters that the current size of the market for medical devices in China is about 300 billion yuan, of which Guangdong accounts for 700-800 million, whose industrial advantage is quite obvious. He suggested that if the future medical device industry can follow the ways of the IT industry, and develop easy-to-operate products oriented to communities and residential users, they will open up a broader market.
 
  Pharmaceutical industry analysts from Anxin Securities, Hong Lu, said that China's current medical device market accounts for 14% of the total pharmaceutical market. Compared with the 42% of the global medical device market in relation to the total pharmaceutical market, there is still a huge space for development in terms of consumption restructuring.
 
  She said that in the future the growth rate of China's medical device market will continue to overtake that of the pharmaceutical industry for the following reasons: in the short term, under the new medical reform policy, the state has increased efforts in constructing the primary health care service system. “Filling the gap" and "upgrading old facilities” will promote the rapid growth of the low-end medical device market, while consumption upgrade, aging population, and technological revolution are the endogenous driving force that promote the long-term rapid growth of China's medical device market.
 
  In her view, the investment opportunities of leading medical device enterprises are worthy of attention: Lepu Medical dedicated to the cardiovascular field, domestic leading manufacturer of high-end supplies Weigao Holdings, leader in the field of cardiac stents MicroPort, and leading equipment manufacturer Mindray Medical whose technologies have reached the international leading level.
 
  Attractive profitability of vaccinesAccording to Rui Guozhong, the global vaccine market size is up to $ 38 billion, while the share of China is only 5-6 billion yuan. China has become the world's largest vaccine producer, which can produce 27 kinds of vaccines preventing 46 kinds of diseases, with an annual output of more than 1 billion dosage units, of which 30% are Class Ⅰ vaccines, and 70% are Class Ⅱ vaccines.
 
  In fact, the Class II vaccine has the most promising future prospects, whose market demand will show a sharper growth. “The market demand for pneumococcal vaccines is around 20 million, which are sold at 150 yuan each on average in the domestic market, so the pneumococcal vaccines alone will have a total market amount of 3 billion yuan”, estimated Rui Guozhong.
 
  Domestic leading producer of vaccines - Hualan Biology will remain its promising position in the eyes of investors. Yuan Jianbo, analyst from Donghai Securities, pointed out in his research report that in terms of vaccine products, the growth rate of the company's seasonal flu vaccines and the tetravalent vaccines increases has risen up; at the same time, the ACYW135 meningococcal polysaccharide vaccine and recombinant hepatitis B vaccine (yeast) are also expected to become a new growth point of the company.
 
  It is primarily expected that the hepatitis B vaccine with a market size of 50 billion has also received sustained attention from the capital market. Xingye Securities has been optimistic about the prospects of the hepatitis B vaccine made by Chongqing Brewery since 2009. In October 10, Xinye Securities rated Chongqing Brewery as the “highly recommended”. Analyst Wang Xi said, “the company’s progress in clinical has validated our judgment. We believe that compared with the existing drugs, this vaccine has obvious efficiencies and less side effects. It is very likely to become a first-line drug, and will have a broad market space in the future.”
Previous: None
Next: None
Previous: None
Next: None